Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/26/2025 07:19 PDT] SLNO Expected to Trade Up After Bullish Patterns Develop
• [06/24/2025 07:29 PDT] SLNO Expected to Trade Up After Bullish Patterns Develop
• [06/12/2025 07:33 PDT] SLNO Expected to Trade Up After Bullish Patterns Develop
• [05/27/2025 07:25 PDT] SLNO Expected to Trade Up After Bullish Patterns Develop
• [05/23/2025 07:49 PDT] SLNO Expected to Trade Up After Bullish Patterns Develop
• [05/22/2025 07:25 PDT] SLNO Expected to Trade Up After Bullish Patterns Develop
• [05/07/2025 06:54 PDT] SLNO Expected to Trade Up After Bullish Patterns Develop